Nuclera (Cambridge, UK), a fast-growing biotech company developing enzymatic protein and gene synthesis technologies, and E Ink (Billerica, Massachusetts), a leading innovator of electronic ink technology, have announced the acquisition of E Ink’s digital microfluidics unit into the newly formed US subsidiary of Nuclera. Combining the technologies of the two companies will enable the delivery of a revolutionary desktop protein and gene “bioprinter” with breakthrough speed and convenience for researchers in human health, agriculture, and other markets of global importance.
The global semiconductor market is growing rapidly. The growth is driven by advancements in IoT, automotive and 5G requiring faster chips that use less power. EUV lithography is a giant leap forward, yet defects in printing remain the greatest constraint to EUV uptake. Silicon is reaching its physical limits too, calling for new material innovations to keep Moore’s Law on track.
Epishine (Linköping, Sweden) and Optiqo (Linköping, Sweden) are cooperating to optimise Optiqo's QlvrBox, which currently operates on batteries, enabling the device to be installed independently of the facility’s infrastructure. This feature offers a great benefit when installing the boxes, however the batteries need to be replaced every 1-3 years. The new version of QlvrBox is developed using Epishine's light energy harvesting solution, and is thus powered by ordinary indoor lighting.
